Jazz gets its narcolepsy upgrade drug decked out for the FDA as clock ticks down on cash cow patents
Jazz Pharmaceuticals $JAZZ appears to be riding its follow-up narcolepsy drug to a near-term approval — just ahead of the generic competition likely to eat up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
